Ann: Clinical Trial Preliminary Outcomes, page-152

No results seem to be available to you or me. Only to the people who were at the conference. As they have been for several days. The announcement is price sensitive, the market reacted accordingly. There is problem number one for the company; timely disclosure.

Problem number two. The ASX has a code for life sciences companies reporting trial results. There is a proper format to be followed. This remains the case even when preliminary results are reported (see page 11).

The company has produced a completely non-complying results announcement. There are very good reasons for each of the reporting elements in the code. Without these elements being present the veracity of trial results cannot be properly assessed.
http://www.asx.com.au/documents/res...e_for_Reporting_by_Life_Science_Companies.pdf

On CE Mark and TGA approval.

CE mark approval doesn’t say the device actually works. It simply says that the device is made consistently to standards and that you can trace where everything came from.

TGA approval – a low risk device gets virtually no scrutiny of efficacy evidence. There are hundreds of these devices TGA listed that are useless.